MiniMed Group, Inc. (MMED), a diabetes technology company, reported that its insulin pumps drive demand for continuous glucose monitors (CGMs) and related consumables, creating a steady recurring revenue stream. The company highlighted new sensors and a dosing algorithm in its Q1 FY2027 update, expected to enhance its value proposition to customers. Although the latest quarter was cash flow intensive due to temporary separation costs, management anticipates improved cash flow in the long term as these costs diminish. With a relatively low valuation and an upcoming product cycle, MMED appears attractive for long-term investors.
Baidu announced that its Class A ordinary shares listed on the Hong Kong Stock Exchange will be included in the Shanghai-Hong Kong Stock Connect program starting September 7, 2026. This inclusion allows eligible mainland Chinese investors to directly...
Curaleaf Holdings has opened a new cannabis dispensary in Riverview, Florida, marking its 77th location in the state and 178th across the U.S. This expansion reflects Curaleaf's strategy to grow its presence in Florida's fast-growing medical cannabis...
SpaceX's stock currently trades below its first closing price despite a strong IPO debut, with a consensus analyst target price about 48% higher than the current price. Raymond James analyst Brian Gesuale projects a much more optimistic outlook, sett...
Critical Metals has consolidated 92.5% ownership of the Tanbreez heavy rare earths project and secured a 15-year offtake agreement with REalloys. The company has started a 10,000-meter drilling program to better define its resources. Tanbreez stands ...
Xcel Energy declared a quarterly dividend of $0.5925 per share, continuing its streak of annual dividend increases aligned with its 4%-6% raise policy. The company operates as a regulated utility, providing predictable cash flows supported by state-a...
